Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


340B Orphan Drug Exclusion Seems Untenable, Sen. Hatch Tells HRSA

This article was originally published in The Pink Sheet Daily

Executive Summary

Following the Health Resources and Services Administration’s final rule on excluding orphan drugs from the 340B discount, Sen. Hatch writes to object to the agency’s interpretation of the statutory language.

You may also be interested in...

340B Final Rule Keeps Orphan Drug Exclusion Narrow, Counter To Manufacturers’ Request

HRSA’s final rule on the exclusion of orphan drugs from 340B discounts says the exclusion applies only to the FDA-designated orphan indication, not all uses of a drug with a rare-disease designation.

Senior Senators Seek Details On Government Audits Of 340B Entities

Top Republicans on two Senate health committees are joined by House members in seeking answers on an HHS review of entities receiving 340B drug discounts, including the process and consequences of audits and decertification.

GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds

New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts